BIOHAVEN RESEARCH RSS Feed | Nachrichten - www.finanzen.netwww.finanzen.net bietet Finanznachrichten zum weltweiten BörsengeschehenFinanzenhttps://www.finanzen.netde-definanzen.net GmbHThu, 30 Apr 2026 23:40:58 +0200https://images.finanzen.net/images/finanzen_net_neu.gifBIOHAVEN RESEARCH RSS Feed | Nachrichten - www.finanzen.nethttps://www.finanzen.netBiohaven Research stellte Ergebnisse des abgelaufenen Quartals vorThu, 05 Mar 2026 06:35:06 +0100https://www.finanzen.net/nachricht/aktien/biohaven-research-stellte-ergebnisse-des-abgelaufenen-quartals-vor-15535698Biohaven Research präsentierte am 02.03.2026 die Bilanzzahlen zum am 31.12.2025 beendeten Jahresviertel.Der Verlust je Aktie belief sich auf 1,21 USD. Im Vorjahresquartal waren -1,850 USD je Aktie in den Büchern ...

]]>https://www.finanzen.net/nachricht/aktien/biohaven-research-stellte-ergebnisse-des-abgelaufenen-quartals-vor-15535698Biohaven Highlights Portfolio Progress, Positive Early Patient Data from Priority Degrader Programs and Anticipated Milestones at the 44th Annual J.P. Morgan Healthcare ConferenceMon, 12 Jan 2026 17:15:00 +0100https://www.finanzen.net/nachricht/aktien/biohaven-highlights-portfolio-progress-positive-early-patient-data-from-priority-degrader-programs-and-anticipated-milestones-at-the-44th-annual-j-p-morgan-healthcare-conference-15410066
  • Reports positive early clinical experience from first and only clinically validated, extracellular protein degraders using Biohaven's proprietary MoDE™ and next-generation, highly selective TRAP™ ...

    ]]>https://www.finanzen.net/nachricht/aktien/biohaven-highlights-portfolio-progress-positive-early-patient-data-from-priority-degrader-programs-and-anticipated-milestones-at-the-44th-annual-j-p-morgan-healthcare-conference-15410066Biohaven to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026Wed, 07 Jan 2026 13:00:00 +0100https://www.finanzen.net/nachricht/aktien/biohaven-to-present-at-the-44th-annual-j-p-morgan-healthcare-conference-on-january-12-2026-15398535

    NEW HAVEN, Conn., Jan. 7, 2026 /PRNewswire/ -- Biohaven Ltd. (NYSE: BHVN) today announced that Vlad ...

    ]]>    https://www.finanzen.net/nachricht/aktien/biohaven-to-present-at-the-44th-annual-j-p-morgan-healthcare-conference-on-january-12-2026-15398535    Biohaven Provides Update From Phase 2 Proof-of-Concept Study with BHV-7000 in Major Depressive DisorderWed, 24 Dec 2025 19:00:00 +0100https://www.finanzen.net/nachricht/aktien/biohaven-provides-update-from-phase-2-proof-of-concept-study-with-bhv-7000-in-major-depressive-disorder-15379236

    NEW HAVEN, Conn., Dec. 24, 2025 /PRNewswire/ -- Biohaven Ltd. (NYSE: BHVN) ("Biohaven"), a global clinical-stage biopharmaceutical ...

    ]]>    https://www.finanzen.net/nachricht/aktien/biohaven-provides-update-from-phase-2-proof-of-concept-study-with-bhv-7000-in-major-depressive-disorder-15379236    Biohaven Presents Clinical Safety and Efficacy Data for BHV-1510, a Next-Generation Trop2 Antibody Drug Conjugate in Combination with Cemiplimab at the 2025 European Society for Medical Oncology (...Thu, 11 Dec 2025 13:00:00 +0100https://www.finanzen.net/nachricht/aktien/biohaven-presents-clinical-safety-and-efficacy-data-for-bhv-1510-a-next-generation-trop2-antibody-drug-conjugate-in-combination-with-cemiplimab-at-the-2025-european-society-for-medical-oncology-15351924
    • In a pretreated population of participants with advanced/metastatic cancer and the majority with prior PD-(L)1 treatment, BHV-1510 2.5 mg/kg Q3W plus cemiplimab resulted in confirmed objective response ...

      ]]>https://www.finanzen.net/nachricht/aktien/biohaven-presents-clinical-safety-and-efficacy-data-for-bhv-1510-a-next-generation-trop2-antibody-drug-conjugate-in-combination-with-cemiplimab-at-the-2025-european-society-for-medical-oncology-15351924Biohaven Research stellte das Zahlenwerk zum vergangenen Quartal vorTue, 11 Nov 2025 06:35:06 +0100https://www.finanzen.net/nachricht/aktien/biohaven-research-stellte-das-zahlenwerk-zum-vergangenen-quartal-vor-15258151Biohaven Research stellte am 10.11.2025 die jüngste Quartalsbilanz zum am 30.09.2025 abgelaufenen Quartal vor.In Sachen EPS wurde ein Verlust von 1,64 USD je Aktie ausgewiesen. Im vergangenen Jahr hatte Biohaven ...

      ]]>      https://www.finanzen.net/nachricht/aktien/biohaven-research-stellte-das-zahlenwerk-zum-vergangenen-quartal-vor-15258151      Biohaven Reports Third Quarter 2025 Financial Results and Recent Business DevelopmentsMon, 10 Nov 2025 12:58:00 +0100https://www.finanzen.net/nachricht/aktien/biohaven-reports-third-quarter-2025-financial-results-and-recent-business-developments-15249113

      NEW HAVEN, Conn., Nov. 10, 2025 /PRNewswire/ -- Biohaven Ltd. (NYSE: BHVN) (Biohaven or the Company), ...

      ]]>      https://www.finanzen.net/nachricht/aktien/biohaven-reports-third-quarter-2025-financial-results-and-recent-business-developments-15249113      FDA Issues Complete Response Letter for Biohaven's VYGLXIA (troriluzole) New Drug Application for Spinocerebellar AtaxiaWed, 05 Nov 2025 02:06:00 +0100https://www.finanzen.net/nachricht/aktien/fda-issues-complete-response-letter-for-biohaven-s-vyglxia-troriluzole-new-drug-application-for-spinocerebellar-ataxia-15190693
      • The troriluzole clinical development program encompassed the first industry clinical trials to generate data showing therapeutic potential in patients with spinocerebellar ataxia (SCA), a rare ...

        ]]>https://www.finanzen.net/nachricht/aktien/fda-issues-complete-response-letter-for-biohaven-s-vyglxia-troriluzole-new-drug-application-for-spinocerebellar-ataxia-15190693